Ovid crashes out in Angelman syndrome
The failure of OV101 puts the spotlight on Ultragenyx and Roche.
Clinical data focus for the smallest players
Our final look at upcoming catalysts sees data expected from Replimune, TCR2 Therapeutics, Anavex and more.
Ovid joins the rare epilepsy race
Ovid Therapeutics gets a mid-stage win in Dravet syndrome, but might have a hard time going up against Zogenix’s Fintepla.
Rare diseases dominate catalysts for the smallest companies
Our final look at third-quarter events focuses this time on the smallest players, with data from Amryt, Ovid, Bellus and more.
First fragile X test is approved, and Zynerba could benefit
The fragile X pipeline is strewn with failures, and crunch time is approaching for Zynerba’s cannabinoid.
Biotech floats come back with a vengeance
The biotech IPO market records its first billion dollar quarter in two years as demand for new issues recovers.
